Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells

Potential use of rapamycin in HIV infection

(2010) Marco Donia et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

(2010) John D. Hainsworth et al.   CANCER

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer

(2010) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

The mTOR Pathway: A New Target in Cancer Therapy

(2010) L. Ciuffreda et al.   CURRENT CANCER DRUG TARGETS

Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO

(2010) Sanja Mijatovic et al.   FREE RADICAL BIOLOGY AND MEDICINE

Key factors in mTOR regulation

(2009) Xiaochun Bai et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series

(2009) Gianluigi Lunardi et al.   CLINICAL THERAPEUTICS

The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis

(2009) Marco Donia et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Considerations in sirolimus use in the early and late post-transplant periods

(2009) Samir J Patel et al.   Expert Opinion On Drug Safety

The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt

(2009) D. Maksimovic-Ivanic et al.   MOLECULAR CANCER THERAPEUTICS

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

(2008) C Le Tourneau et al.   BRITISH JOURNAL OF CANCER

Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer

(2008) Robert J. Amato et al.   Clinical Genitourinary Cancer

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

(2008) Paolo Baldo et al.   CURRENT CANCER DRUG TARGETS

mTOR: The Mammalian Target of Replication

(2008) Ezra E.W. Cohen   JOURNAL OF CLINICAL ONCOLOGY

Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo

(2008) D. Maksimovic-Ivanic et al.   MOLECULAR CANCER THERAPEUTICS

Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid–nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells

(2008) Sanja Mijatovic et al.   NITRIC OXIDE-BIOLOGY AND CHEMISTRY